3rd Quarter - Report

VIR BIOTECHNOLOGY, INC. for VIR BIOTECHNOLOGY, INC.

Firm
Client
Income
—
Expenses
$170,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Reimbursement of COVID-19 Therapeutics

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS)

Science/Technology SCI

Pandemic Preparedness

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

S. 2640, Disease X Act; H.Res. 601, FY 2022 Budget Resolution and Reconciliation Instructions, S. Con. Res. 14 FY 2022 Budget Resolution and Reconciliation Instructions; Prescription Policy in Budget Reconciliation; American Rescue Plan Implementation (COVID-19 Response and COVID Therapeutics Procurements), Pandemic Preparedness.

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 2640 (117th), S.Con.Res. 14 (117th), H.Res. 601 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.